- Based on the market research of peptide drugs in the above-mentioned therapeutic fields, the company carefully selects 2-3 peptide drugs in each field for echelon research and development.
- In terms of the regional distribution of the global market, the United States and Europe are currently the most important markets for peptide drugs.
Based on the market research of peptide drugs in the above-mentioned therapeutic fields, the company carefully selects 2-3 peptide drugs in each field for echelon research and development.
The product line covers multiple treatment areas. The main varieties in the field of peptide drug therapy and the company’s existing and under-development products and their comparisons are as follows:
According to QYResearch statistics: the global peptide drug market scale was approximately US$15.2 billion in 2010 and reached US$28.5 billion in 2018, with a compound annual growth rate of 8.17%, compared to the global pharmaceutical market of approximately US$1.3 trillion in 2018 , The market size of peptide drugs accounted for only 2.19%, and the growth rate of the market size of peptide drugs was approximately twice that of the overall growth rate of the global drug market.
The peptide drug market is expected to grow at a compound annual growth rate of 7.9% in the future, and the market size will reach 49.5 billion US dollars in 2027. The peptide drug market still has huge room for growth.
In terms of the regional distribution of the global market, the United States and Europe are currently the most important markets for peptide drugs.
The North American market accounts for the largest proportion of the global market. It is expected that the Asian region will be the fastest-growing region in the peptide drug market. Increasing medical expenditures and the focus on innovative treatments will drive the growth of the peptide therapy market in the Asia-Pacific region.
At present, dozens of peptide drugs in the global market have shown great clinical application value and wide application prospects. Many peptide drugs have become varieties exceeding hundreds of millions of dollars in just one or two years after they are on the market.
In 2016, there were 6 peptide drugs with annual sales of more than 1 billion U.S. dollars, such as Teva Pharmaceuticals (TEVA) glatiramer, which has accounted for 20% of the multiple sclerosis market, with global sales of approximately 4.2 billion U.S. dollars; Novo NovoNordisk’s liraglutide, which is used to treat type II diabetes, has sales of over US$2.8 billion and is a blockbuster product of peptide drugs.
According to data from Evaluatepharma and PDB, the research institutes of pharmaceuticals, the market size of orphan diseases/rare diseases, tumors, and diabetes in peptide drugs are all over 3 billion U.S. dollars, while the remaining four fields, digestive tract, orthopedics, immunity, and cardiovascular and cerebrovascular are relatively Smaller, but there are also some heavy varieties.
In terms of competition, the development of peptide drugs requires huge amounts of money and time, and barriers are high. Multinational pharmaceutical giants in developed countries in Europe and the United States have basically monopolized the super varieties of peptide drugs on the market by virtue of their capital investment and R&D level advantages.
At the same time, European and American countries generally implement very strict drug patent systems and drug market exclusivity systems, with patent protection periods ranging from 8 to 20 years. According to statistics from Ferring Pharmaceutical Research Institute in 2016, the top 10 peptide pharmaceutical companies in the world include Teva, NovoNordisk, Novartis, AstraZeneca, EliLilly , Takeda (Takeda), Amgen (Amgen), Ferring (Ferring Pharmaceuticals), etc.
Although my country’s peptide drug market started late, it has developed rapidly. Sales rose from 5.6 billion yuan in 2009 to 29.56 billion yuan in 2017, with an average compound annual growth rate of 23.12%, which is much higher than the overall growth of the global peptide drug market.
speed. With the introduction of my country’s policies to encourage the research and development of innovative drugs and promote the consistency evaluation of generic drugs, it is expected that more innovative peptide drugs and peptide generic drugs with significant clinical effects will be approved for marketing in the future, which will further expand the peptide drug market in my country.